

Medical Biochemistry

Eight Things Clinicians and Patients Should Question

by
Canadian Association of Medical Biochemists
Last updated: May 2024



1 Don't order serum folate testing in the absence of the following: anemia with red blood cell macrocytes or hypersegmented polynuclear neutrophils and a reasonable clinical suspicion of a nutritional deficiency such as an unsupplemented restrictive diet, severe Alcohol Use Disorder, or malabsorption.

Since 1998, all wheat white flours for food use sold in Canada and United States are enriched with folic acid as a mandatory legal requirement. The main reason for this supplementation is to prevent neural tube defects in newborns. Folates are found in processed food that contains white flour and in green leafy vegetables, legumes, some fruits and beans. Folate deficiency is therefore now encountered very rarely in Canada.

For most patients at risk for folate deficiency, like those with malabsorption, it is more practical and economical to treat with multivitamin supplements including folic acid, than to test for deficiency.

The Society of Obstetricians and Gynecologists of Canada recommends universal supplementation for women in the reproductive age group. Investigations are not required prior to initiating folic acid in women considering pregnancy.

2 Don't order an erythrocyte sedimentation rate (ESR) to screen asymptomatic patients or as a general test to look for inflammation in patients with undiagnosed conditions.

ESR is a non-specific inflammation marker influenced by various factors including anemia, pregnancy, and smoking. C-reactive protein (CRP) is a less expensive and more sensitive and specific reflection of the acute phase of inflammation, hence should be used for this purpose. In the first 24 hours of a disease process, the CRP will be elevated, while the ESR may be normal. If the source of inflammation is removed, CRP will normalize within a day or so, while ESR will remain elevated for days. Only CRP should be used as a measure of systemic inflammation.

3 Don't order amylase in addition to lipase to detect pancreatitis.

In pancreatitis, levels of amylase and lipase have been found to correlate very well. However, multiple studies have shown that lipase is a more sensitive and specific marker of acute pancreatitis than amylase. Moreover, lipase stays elevated longer than amylase, which is useful in cases of delayed presentation. However, false negative results may still be observed after many days, but amylase is not helpful in those cases. For children, pediatric specific reference ranges should be adapted.

4 Don't request a serum protein electrophoresis in asymptomatic patients in the absence of otherwise unexplained hypercalcemia, renal insufficiency, anemia or lytic bone lesions.

Serum protein electrophoresis (SPE) is mainly indicated to detect monoclonal gammopathy in patients who have clinical symptoms and signs related to multiple myeloma, amyloidosis, or Waldenstrom macroglobulinemia. It may also be performed in certain uncommon diseases associated with a monoclonal protein like POEMS syndrome and some forms of polyneuropathy.

About 3% of the population above the age of 50, have a monoclonal gammopathy of undetermined significance (MGUS). Current practice guidelines do not recommend routine screening for MGUS in the general population because of the lack of proven benefit, absence of actionable preventive therapy and creation of unnecessary anxiety for some patients.

SPE is not a sensitive test to detect inflammation, C-reactive protein is a better and less costly alternative that is more responsive to changes in the patient status.

5 Don't request uric acid as part of the routine evaluation of cardiovascular risk, obesity or diabetes.

Although evidence of a causative link between hyperuricemia and cardiometabolic risk is mounting, it still does not support the use of pharmacotherapy and its concentration is not used in equations for estimating vascular risk. Asymptomatic hyperuricemia is a frequent, coincidental, biochemical finding that does not require any treatment.

Uric acid should not be measured routinely, but its measurement may be considered mainly in the following situations:

- Investigation of acute joint pain
- Follow-up of hypouricemic treatment
- Follow-up of patients with kidney disease and kidney stone disease
- Preeclampsia
- Tumor lysis syndrome

6 Don't order serum total bile acids to assess cholestasis in non-pregnant women and general populations.

Serum total bile acids tests (TBA) are used primarily for the evaluation and monitoring of intrahepatic cholestasis of pregnancy (ICP), a condition affecting 1-2% of pregnant women in North America. ICP is associated with an increased risk of perinatal complications including premature birth, intrauterine asphyxia, fetal bradycardia and even stillbirth. Severe ICP is defined when serum TBA is above 40 $\mu\text{mol/L}$, and the likelihood of stillbirth is significantly increased when the serum TBA concentration is $>100\text{mmol/L}$, which makes it a good prognostic marker. However, in non-pregnant individuals with suspected cholestasis, TBA is not an effective test to assess liver dysfunction compared to traditional liver panel tests (e.g., bilirubin, albumin, ALT, GGT and ALP). In the context of familial intrahepatic cholestasis, the serum TBA is considered as a tier 2 investigation which is ordered by pediatric gastroenterologists only. The urine bile acids profile is the appropriate test for the investigation of disorders of bile acid synthesis, not serum TBA.

7 Don't order copper and ceruloplasmin as routine screening tests for children with global developmental delay/intellectual disability.

Global developmental delay and intellectual disability (GDD/ID) affect 3% of the paediatric population. Since its differential diagnosis is broad, community-based clinicians tend to order copper and ceruloplasmin tests to screen for Wilson's and Menkes disease (mutations in ATP7A or ATP7B). However, a recent study determined that neither Wilson's nor Menkes disease have been identified using these tests in children with global developmental delay/intellectual disability. In addition, false abnormal copper and ceruloplasmin results lead to an increase in the number of total referrals and unnecessary follow ups (4% in the above study). Children with Wilson's disease are more likely to present with hepatic manifestations than neurologic symptoms, while those with Menkes disease show multiple abnormalities including developmental delay and epilepsy typically within the first 3 months of life.

8 Do not utilize point-of-care testing where centralized labs can offer clinically acceptable turnaround reporting.

POCT should be strategically utilized only in scenarios where it significantly influences immediate treatment decisions and offers a distinct advantage over traditional laboratory testing. Unlike laboratory-based tests, POCT may lead to more frequent false results potentially causing misdiagnoses, incorrect treatment decisions, and unnecessary additional testing or procedures contributing to further increased costs and medical waste. POCT's reliance on single use, fossil-derived plastics, not only generates considerable waste but also poses environmental and health risks through potential toxic emissions from incineration.

How the list was created

The list was developed under the guidance of a committee formed with the specific intent of producing a list of 5 recommendations. All CAMB members were invited to participate and members were nominated by the CAMB board executive. The committee members reviewed the CWC guidance on producing recommendations and put forward a number of topics that were refined in discussion during committee meetings. A preliminary list of 22 topics was produced by the committee. A survey of all the membership was conducted by an electronic survey with options to add more suggestions. The ranked result of the survey was discussed with the committee and duplicate results were not considered. Weighting of each topic was reviewed and a list of 5 topics was agreed upon.

Recommendations 6 & 7 were approved by the executive board of the Canadian Association of Medical Biochemists (CAMB) in May 2022. These recommendations were further revised by the CAMB Choosing Wisely Canada committee in September 2022. Additionally, a rapid literature review to confirm recommendation 7 was conducted by CADTH in December 2022. The final English version of the recommendations as well as their French translations were approved by all the CAMB members in March 2023.

Sources

- 1** Ashraf MJ, Cook JR, Rothberg MB. Clinical utility of folic acid testing for patients with anemia or dementia. *J Gen Intern Med.* 2008 Jun;23(6):824-6. PMID: [18414954](#).
Brian M. Gilfix. Utility of measuring serum or red blood cell folate in the era of folate fortification of flour. *Clinical Biochemistry.* 2014 May;47(7-8):533-8. PMID: [24486651](#).
Hennessy-Priest K, Mustard J, Keller H, Rysdale L, Beyers J, Goy R, Randall Simpson J. Folic acid food fortification prevents inadequate folate intake among preschoolers from Ontario. *Public Health Nutr.* 2009 Sep;12(9):1548-55. PMID: [19200405](#).
MacFarlane AJ, Greene-Finestone LS, Shi Y. Vitamin B-12 and homocysteine status in a folate-replete population: results from the Canadian Health Measures Survey. *Am J Clin Nutr.* 2011 Oct;94(4):1079-87. PMID: [21900461](#).
Ray JG. Efficacy of Canadian folic acid food fortification. *Food Nutr Bull.* 2008 Jun;29(2 Suppl): S225-30. PMID: [18709897](#).
Theisen-Toupal J, Horowitz G, Breu A. Low yield of outpatient serum folate testing: eleven years of experience. *JAMA Intern Med.* 2014 Oct;174(10):1696-7. PMID: [25111789](#).
Wilson RD et al; Genetics Committee, Society of Obstetricians and Gynaecologists of Canada. Pre-conception Folic Acid and Multivitamin Supplementation for the Primary and Secondary Prevention of Neural Tube Defects and Other Folic Acid-Sensitive Congenital Anomalies. *J Obstet Gynaecol Can.* 2015 Jun;37(6):534-52. PMID: [26334606](#).
- 2** Assasi N, Blackhouse G, Campbell K, Hopkins RB, Levine M, Richter T, Budden A. [Comparative Value of Erythrocyte Sedimentation Rate \(ESR\) and C-Reactive Protein \(CRP\) Testing in Combination Versus Individually for the Diagnosis of Undifferentiated Patients With Suspected Inflammatory Disease or Serious Infection: A Systematic Review and Economic Analysis.](#) Ottawa : Canadian Agency for Drugs and Technologies in Health; 2015 Nov. (CADTH no. 40). [Internet].
Brigden ML. Clinical utility of the erythrocyte sedimentation rate. *Am Fam Physician.* 1999 Oct 1;60(5):1443-50. PMID: [10524488](#).
Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review. *JAMA.* 2016 Jun 14;315(22):2442-58. PMID: [27299619](#).
Harrison M. Erythrocyte sedimentation rate and C-reactive protein. *Harrison M1. Aust Prescr.* 2015 Jun;38(3):93-4. PMID: [26648629](#).
Mönig H, Marquardt D, Arendt T and Kloehn S. Limited value of elevated erythrocyte sedimentation rate as an indicator of malignancy. *Family Practice* 2002 Oct;19(5):436-8. PMID: [12356689](#).
- 3** Abu-El-Haija M, Kumar S, Quiros JA, et al. Management of Acute Pancreatitis in the Pediatric Population: A Clinical Report From the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Pancreas Committee. *J Pediatr Gastroenterol Nutr.* 2018 Jan;66(1):159-176. PMID: [29280782](#).
American Gastroenterological Association (AGA). AGA Institute medical position statement on acute pancreatitis. *Gastroenterology* 2007;132(5):2019-21. PMID: [17484893](#).
Haute Autorité de Santé (HAS). [Évaluation de l'amylasémie et de la lipasémie pour le diagnostic initial de la pancréatite aiguë.](#) Rapport d'évaluation technologique. Saint-Denis la Plaine, France : HAS; 2009. [Internet].
Ismail OZ, Bhayana V. Lipase or amylase for the diagnosis of acute pancreatitis? *Clin Biochem.* 2017 Dec; 50(18):1275-1280. PMID: [28720341](#).
United Kingdom Working on Acute Pancreatitis (UKPAP). UK guidelines for the management of acute pancreatitis. *Gut* 2005; 54(Suppl3)1-9. PMID: [15831893](#).
Ventrucci M, Pezzilli R, Naldoni P, Platè L, Baldoni F, Gullo L, Barbara L. Serum pancreatic enzyme behavior during the course of acute pancreatitis. *Pancreas.* 1987;2(5):506-9. PMID: [2444967](#).
- 4** Alberta Health Services (AHS). [Multiple myeloma. Clinical practice guideline LYHE-003.](#) Calgary, AB 2015
Chami N, Simons JE, Sweetman A, Don-Wauchope AC. Rates of inappropriate laboratory test utilization in Ontario. *Clin Biochem.* 2017 Oct;50(15):822-827. PMID: [28483406](#).
Go RS, Rajkumar SV. How I manage monoclonal gammopathy of undetermined significance. *Blood.* 2018 Jan 11;131(2):163-173. PMID: [29183887](#).
Institut national d'excellence en santé et en services sociaux (INESSS). [Usage judicieux de 14 analyses biomédicales. Rapport rédigé par Faiza Boughrassa et Alicia Framarin avec la collaboration du Comité d'experts sur la pertinence-OPTILAB.](#) Montréal, Québec : INESSS; 2014. 33p. [Internet].
Khouri J, Samaras C, Valent J, et al. Monoclonal gammopathy of undetermined significance: A primary care guide. *Cleve Clin J Med.* 2019 Jan;86(1):39-46. PMID: [30624183](#).
Moreau P, San Miguel J, Sonneveld P, et al.; ESMO Guidelines Committee. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2017 Jul 1;28(suppl_4):iv52-iv61. PMID: [28453614](#).
- 5** James W Lohr et al. [Hyperuricemia treatment and management.](#) August 2018. [Internet].
Khanna D, et al. American College of Rheumatology Guidelines for Management of Gout. Part 1: Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia. *Arthritis Care Res (Hoboken).* 2012 Oct;64(10):1431-46. PMID: [23024028](#).
Paul BJ et al. Asymptomatic hyperuricemia: is it time to intervene? *Clinical Rheumatology.* 2017 Dec;36(12):2637-2644. PMID: [28980141](#).
Stamp L, Dalbeth N. Urate lowering therapy for asymptomatic hyperuricemia. A need for caution. *Semin Arthritis Rheum.* 2017 Feb;46(4):457-464. PMID: [27591828](#).

- 6 Azer, S.A. et al. Use of bile acids as potential markers of liver dysfunction in humans: A systematic review. *Medicine (Baltimore)*. 2021 Oct 15;100(41):e27464. PMID: 34731122.
- Fawaz R et al. Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. *J Pediatr Gastroenterol Nutr*. 2017 Jan;64(1):154-168. PMID: 27429428.
- Piechota, J. et al. Intrahepatic cholestasis in pregnancy: Review of the literature. *J Clin Med*. 2020 May 6;9(5):1361. PMID: 32384779.
- Ovadia, C. et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. *Lancet*. 2019 Mar 2;393(10174):899-909. PMID: 30773280.
- 7 Shribman, S. et al. Clinical presentations of Wilson disease. *Ann Transl Med*. 2019 Apr;7(Suppl 2):S60. PMID: 31179297.
- Vairo, F.P.E. et al. A systematic review and evidence-based guideline for diagnosis and treatment of Menkes disease. *Mol Genet Metab*. 2019 Jan;126(1):6-13. PMID: 30594472.
- Vallance, H. et al. Diagnostic yield from routine metabolic screening tests in evaluation of global developmental delay and intellectual disability. *Paediatr Child Health*. 2020 Dec 19;26(6):344-348. PMID: 34676012.
- 8 Canada's Drug Agency: [Evidence on Point-of-Care Testing](#) | CADTH.
- Lingervelder D, Koffijberg H, Kusters R, et al. Health Economic Evidence of Point-of-Care Testing: A Systematic Review. *Pharmacoecoon Open*. 2021 Jun;5(2):157-173. PMID: 33405188.
- Ongaro AE, Ndllovu Z, Sollier E, Otieno C, Ondoa P, Street A, Kersaudy-Kerhoas M. Engineering a sustainable future for point-of-care diagnostics and single-use microfluidic devices. *Lab Chip*. 2022 Aug 23;22(17):3122-3137. PMID: 35899603.
- Ortiz DA, Loeffelholz MJ. Practical Challenges of Point-of-Care Testing. *Clin Lab Med*. PMID: 37169439.

About the Canadian Association of Medical Biochemists

The CAMB is the national association that represents physicians specialized in medical biochemistry, a specialty recognized by the Royal College of Physicians and Surgeons of Canada. Medical Biochemists directs clinical laboratories, consults, diagnoses and treats patients with a variety of metabolic disorders and biochemical abnormalities. The CAMB promotes quality and security in laboratory medicine and in the clinical use of laboratory information through education, research, and clinical practice. The CAMB aims to serve and educate the public and also to enhance career opportunities of its members through continuous professional development and advocacy initiatives.



About Choosing Wisely Canada

Choosing Wisely Canada is the national voice for reducing unnecessary tests and treatments in health care. One of its important functions is to help clinicians and patients engage in conversations that lead to smart and effective care choices.

🌐 ChoosingWiselyCanada.org | ✉ info@ChoosingWiselyCanada.org | 🐦 [@ChooseWiselyCA](https://twitter.com/ChooseWiselyCA) | 📌 [/ChoosingWiselyCanada](https://www.facebook.com/ChoosingWiselyCanada)